《大行報告》麥格理升中生製藥(01177.HK)評級至「跑贏大市」 疫苗業務收益強勁
麥格理發表報告指,中生製藥(01177.HK)公布今年首季業績,來自疫苗業務的盈利非常強勁,估計首季有12億元人民幣利潤來自該業務,意味其持股15%及即將公布業績的科興生物(SVA.US)首季盈利或達80億元人民幣。
該行表示,莫德納(MRNA.US)現時新型肺炎疫苗的目標銷售為192億美元,至於輝瑞(PFE.US)目標則為260億美元,兩企於今年首季的毛利率都有約90%,且銷售、一般及行政開支為單位數,估計中生製藥來自疫苗的盈利亦會陸續有來。
麥格理上調中生製藥股份評級,由「中性」升至「跑贏大市」,目標價由8.39元升至10.46元,並調升集團今明兩年每股盈利預測分別62%及33%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.